54.3 F
San Diego
Thursday, Mar 28, 2024
-Advertisement-

MEI Pharma Inc. Announces $45 Million Proposed Public Offering

MEI Pharma Inc., a San Diego-based oncology company focused on clinical development of cancer therapies, announced that it plans to offer up to $45 million in shares of its common stock in an underwritten public offering.

The company plans to use the net proceeds of the offering, together with other available funds, to progress the clinical development programs for Pracinostat, MEI’s lead drug candidate, in acute myeloid leukemia and for other general corporate purposes.

Bank of America Merrill Lynch is acting as sole book-running manager for the offering. Cowen and Company and Stifel are acting as co-lead managers.

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-